SYDNEY, Australia, Oct. 20 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that it had received approval to market Aridol from the Swiss therapeutic regulatory agency Swissmedic.
Aridol is indicated for measuring airway hyperresponsiveness and within Europe is now approved in 13 countries - Denmark, Finland, France, Germany, Greece, Ireland, The Netherlands, Norway, Portugal, Spain, Sweden, Switzerland and the United Kingdom.
"Swiss physicians have been some of the earliest adopters of Aridol, pioneering early clinical trials, so I am delighted to have the product approved there" said Pharmaxis CEO Dr Alan Robertson. "This level of innovation has attracted the attention of two multinational Pharma companies who are currently funding studies in Switzerland that utilize Aridol to diagnose asthma and COPD patients who will respond to inhaled corticosteroids".
Aridol will be distributed in Switzerland by Trimedal, a specialist respiratory and allergy pharmaceutical company based in Zurich, Switzerland. It has an extensive network of contacts with pulmonary specialists, allergists and respiratory laboratories that will be critical for the market success of Aridol. Pricing for Aridol in Switzerland is included under an existing reimbursement code so marketing may commence immediately.
A simple-to-use airways inflammation test, Aridol is a dry powder administered to patients' lungs via a small hand-held inhaler. Doctors can use the results of this test to identify airway hyperresponsiveness - a hallmark of asthma. Medications can be adjusted according to the severity of the disease.
Forward-Looking Statements
The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We can not guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.
For more information, please contact:
Alan Robertson, Chief Executive Officer
Tel: +61-2-9454-7200
Email: alan.robertson@pharmaxis.com.au
RELEASED THROUGH:
Australia:
Felicity Moffatt,
Tel: +61-418-677-701
Email: felicity.moffatt@pharmaxis.com.au
United States:
Brandon Lewis,
Trout Group,
Tel: +1-646-378-2915
Email: blewis@troutgroup.com
